Clinical trials: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
MASLD, Fibrosis of Liver
Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal…
- Trial name
- NCT07305324
- Testing
- FibroX, Usual Care
- Volunteers
- 40 people
- Sponsor
- Yale University
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
MASLD, T2DM (Type 2 Diabetes Mellitus)
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor…
- Conditions
- MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
- Trial name
- ENSURE-MASLD (NCT07172997)
- Testing
- Bariatric Surgery
- Where
- 2 sites in Bahrain
- Volunteers
- 163 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Metabolic Dysfunction-associated Steatotic Liver Disease
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of liver weight not explained by at-risk alcohol…
- Trial name
- MPM (NCT06495333)
- Where
- Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Fundacion de Investigacion Science and Education
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT06947304
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Corcept Therapeutics
MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
This study aims to determine the daily rate of endogenous synthesis of oxalate using fasted urine collection and a low-oxalate controlled diet in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- Trial name
- NCT06735924
- Testing
- Low-oxalate fixed diet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Prevalence and Clinical Significance of Hematological Abnormalities in Patients With Clinically Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Case-Control Study
this study aims to investigate the prevalence of hematological abnormalities among patients with clinically diagnosed MASLD, evaluate their clinical correlates, and examine their association with non-invasive fibrosis scores.
- Trial name
- MASLD (NCT07872059)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Fibrosis and Metabolic Markers in Relation to PREVENT Cardiovascular Risk in MASLD
This retrospective observational study evaluates the relationship between non-invasive liver fibrosis and metabolic markers and estimated cardiovascular risk in adults with metabolic dysfunction-associated steatotic liver disease…
- Trial name
- MASLD-PREVENT (NCT07791589)
- Where
- Turkey (Türkiye)
- Volunteers
- 271 people
- Sponsor
- Özgür Bahadır
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
The goal of this observational study is to establish a multi-center registry to better understand Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) using health screening data from Korean hospitals.
- Trial name
- K-MASLD (NCT06843421)
- Where
- 5 sites in South Korea
- Volunteers
- 6,000 people
- Sponsor
- Korea University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Integrating Hepatological, Nutritional, and Psychological Support as a Multidisciplinary Management to Improve Long-term Clinical Outcomes in MASLD
Metabolic dysfunction associated Steatotic Liver Disease (MASLD) is frequently complicated by cardiometabolic (CMR) comorbidities, and prognosis is substantially influenced by acute cardiovascular events (ACE).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Cardiovascular Events
- Trial name
- CoCoNut (NCT07366463)
- Testing
- Hepatologic-provided recommendations, Nutritional support, Psychological support
- Where
- Italy
- Volunteers
- 286 people
- Sponsor
- University of Campania Luigi Vanvitelli
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic…
- Trial name
- NCT07902219
- Testing
- Qurse Revand
- Where
- India
- Volunteers
- 128 people
- Sponsor
- National Institute of Unani Medicine, Bengaluru
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Combination of CXD and Restrictive Ketogenic Diet Against MASLD
This study employed a single-center, randomized, investigator-blind, three-group parallel, stepwise controlled clinical trial. A total of 135 subjects were randomly assigned to receive either a low-carbohydrate diet intervention…
- Trial name
- NCT07639866
- Testing
- Low-carbon control group, KD group, CXD and KD group
- Volunteers
- 135 people
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital